Technical Analysis for EVO - Evotec SE
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| C | 4.40 | 13.40% | 0.52 |
EVO closed up 13.4 percent on Monday, November 4, 2024, on 3.82 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
Earnings due: Nov 6
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New Uptrend | Bullish | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Volume Surge | Other | 0.00% | |
| Doji - Bearish? | Reversal | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Above Upper BB | Strength | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 13.40% | |
| Volume Surge | Other | 13.40% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakdown | about 10 hours ago |
| 2x Volume Pace | about 10 hours ago |
| 3x Volume Pace | about 10 hours ago |
| 5x Volume Pace | about 10 hours ago |
| Possible Pocket Pivot | about 10 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/06/2024
Evotec is an industry-leading drug discovery and development partner for the pharmaceutical and biotechnology industry. Evotec's mission is to discover best and first-in-class medicines for a broad range of difficult to treat diseases in collaboration with our partners. Evotec has built a comprehensive suite of fully integrated, next generation technology platforms which it believes will transform the way new drugs are discovered. By leveraging the advanced capabilities of Evotec's integrated platforms, Evotec is able to provide solutions to its partners that enable significant improvements in the quality of new drugs while accelerating the drug discovery process and reducing the high cost of attrition often associated with traditional drug discovery processes.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Biotechnology Life Sciences Disease Natural Sciences Health Sciences Drugs Medication Drug Discovery
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Biotechnology Life Sciences Disease Natural Sciences Health Sciences Drugs Medication Drug Discovery
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 11.9999 |
| 52 Week Low | 2.85 |
| Average Volume | 101,270 |
| 200-Day Moving Average | 5.26 |
| 50-Day Moving Average | 3.47 |
| 20-Day Moving Average | 3.45 |
| 10-Day Moving Average | 3.79 |
| Average True Range | 0.17 |
| RSI (14) | 73.82 |
| ADX | 25.92 |
| +DI | 56.51 |
| -DI | 17.21 |
| Chandelier Exit (Long, 3 ATRs) | 3.95 |
| Chandelier Exit (Short, 3 ATRs) | 3.42 |
| Upper Bollinger Bands | 4.26 |
| Lower Bollinger Band | 2.63 |
| Percent B (%b) | 1.09 |
| BandWidth | 47.20 |
| MACD Line | 0.19 |
| MACD Signal Line | 0.08 |
| MACD Histogram | 0.109 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.57 | ||||
| Resistance 3 (R3) | 4.57 | 4.52 | 4.54 | ||
| Resistance 2 (R2) | 4.52 | 4.48 | 4.52 | 4.53 | |
| Resistance 1 (R1) | 4.46 | 4.45 | 4.49 | 4.46 | 4.52 |
| Pivot Point | 4.41 | 4.41 | 4.43 | 4.41 | 4.41 |
| Support 1 (S1) | 4.35 | 4.37 | 4.38 | 4.35 | 4.28 |
| Support 2 (S2) | 4.30 | 4.34 | 4.30 | 4.27 | |
| Support 3 (S3) | 4.24 | 4.30 | 4.26 | ||
| Support 4 (S4) | 4.24 |
